Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. - Test2 - elhamkhani - TriplyDB

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

http://www.wikidata.org/entity/Q33986236

about

Midostaurin: an emerging treatment for acute myeloid leukemia patients Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities Progress in acute myeloid leukemia FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine Novel therapeutic options in Acute Myeloid Leukemia Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia Secondary mutations as mediators of resistance to targeted therapy in leukemia FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients Emerging therapies for acute myeloid leukemia.Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Molecular therapy for acute myeloid leukaemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia The Biology and Targeting of FLT3 in Pediatric Leukemia.The Future of Targeting FLT3 Activation in AML.Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia.Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.Is targeted therapy feasible in acute myelogenous leukemia?CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.Recent advances and novel agents for FLT3 mutated acute myeloid leukemia.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.Evolving treatment strategies in patients with high-risk acute myeloid leukemia.

P2860

Q26749271-5AFB374E-3690-4287-B534-82B58ACC4B05 Q26749870-62829BE3-E97D-4DA6-8099-174FB33B3D7F Q26863756-969163B1-B9ED-49B7-B96F-A1E89D964016 Q27024006-7A291EF5-8623-4EDB-9B04-9D23337B5001 Q27028163-CDAE6F36-5B4A-419E-9DAD-7C89D94267F1 Q27700733-70F7F6A7-9481-4D1D-8B6B-3FAC1B7ECDC9 Q28069889-7BCEC591-70F2-4C80-B64D-F557538E61A3 Q28075654-C4AD669A-3C1E-489B-BF0C-70B47F30BC91 Q28087213-4684E131-1179-4DD8-8DE2-EF2CEA47A634 Q28289859-FA98BB7F-1389-402A-9493-B9D6DCCDDC66 Q28538435-A3998670-4842-40B1-AF5A-512595936845 Q28544659-2E7642C2-726B-4652-BDB4-3049409064BF Q33555287-19DB88FD-442F-4CBC-9B7D-63BD3FD7F476 Q33576363-9EB4266B-5D29-4D7E-89A5-7DDA65044B3C Q33710062-3FBA2FF7-AFBA-41B4-8B30-8D46713A7B20 Q33749036-CBC16D97-28E7-4B56-A09E-9A1B6603A62D Q33767026-FE97A1DD-6AC4-481E-9BCE-8A84677D5E7E Q33770125-63452E5F-BB5A-4CE7-B81E-5943396C2912 Q33925672-41A03EF4-6EEE-4CC0-8A46-DDA2AB356F37 Q33943277-D9F8C346-626E-454B-8C35-56F3084A80B1 Q34229555-EFCFA237-9E9A-4686-AE9D-A910B59794DB Q34555386-20A08E07-C13F-4264-B20C-9479C492C8C8 Q34573775-4FE32810-B1D8-42E9-BEE9-27DB2EA036F0 Q34647741-77E328FB-8BBA-40AB-B2CA-94D1117E2BFC Q35224437-F70E9931-6BFF-48E8-891D-FFE427753FC9 Q35525811-C2C32310-EB59-40F3-BE02-809A1B4849DD Q35750567-C1AA6549-78BA-4E3A-8E2B-17A0BDCD66DE Q35793176-3C266FBC-92DB-4E2B-B85A-60FD9043B631 Q35857472-9C04D34A-8BB1-47EC-9DD6-7D43A2CE6EE8 Q36356082-778C6F8B-73D3-4058-9304-5E7F39FCF42D Q36416358-4108ADE3-3DFB-42D0-953C-E505AF0CD4A2 Q36545966-FC6CFC46-2DA3-4D6D-9141-A2D91CCBDDF6 Q37043763-8E09EA71-1031-43E5-B69A-DD9E4ED6B5F1 Q37221579-F49A56D4-65E5-4BF9-ADBD-B8A62E2833DD Q37325725-856E33D5-A379-42F9-8685-8BD2CA2D7AF5 Q37338371-B3D1D2DD-1DFB-48C6-BC67-765CF18A2C6A Q37706488-FB6992B7-235D-4C94-B26B-EA7193A4A589 Q38101284-0A16BC31-BEEF-4671-9B09-90EEC3A7C047 Q38168893-5DFAEF16-B723-46B3-B1BD-BD8D16B231C6 Q38179026-83D42B33-B12D-4C21-989E-A91ED6A13ADA

P2860

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

http://www.wikidata.org/entity/Q33986236

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase IB study of the FLT3 kin ...... s with acute myeloid leukemia.

@ast

Phase IB study of the FLT3 kin ...... s with acute myeloid leukemia.

@en

type

label

Phase IB study of the FLT3 kin ...... s with acute myeloid leukemia.

@ast

Phase IB study of the FLT3 kin ...... s with acute myeloid leukemia.

@en

prefLabel

Phase IB study of the FLT3 kin ...... s with acute myeloid leukemia.

@ast

Phase IB study of the FLT3 kin ...... s with acute myeloid leukemia.

@en

P1433

Q33986236-28AE9523-8C4C-4552-9A3B-58E7F694C923

P1476

Q33986236-1C348383-D05C-40F8-A5D7-CC77B97949E8

P2093

Q33986236-158027BF-D85D-42EE-A1C3-2849250CC333

Q33986236-201FBCCC-6077-43D2-BB65-27852575DBD5

Q33986236-382F9C10-8315-4047-8024-C61396496C58

Q33986236-458A6073-3833-447D-9F3D-65D65AD753C6

Q33986236-952EC82C-9349-4606-BCE4-7F7AA355B1C4

Q33986236-B8837C32-0F58-4EE1-B138-A8EA3958E3D9

Q33986236-C1EA2D91-0626-46BD-AE43-B8B733C09A24

Q33986236-C8CD62BE-9590-498E-9D14-4CFFAD76326A

Q33986236-CE81C370-BA08-4093-9897-9D387714E162

Q33986236-D0572B83-1F7D-47C7-AD14-058E7940E780

P2860

Q33986236-0E709F1A-62F6-4B92-9BAD-14512732FDC4

Q33986236-270328EB-0784-483A-9B34-B5294DA1C9E2

Q33986236-3AAD3FEF-132D-4EF7-8284-8836E8EEEA82

Q33986236-5094493E-4BAB-488F-A451-61F720AC47B5

Q33986236-5AB30B22-DB4F-4A6A-9869-0A49522DF5B3

Q33986236-64B3E70E-2D7D-421E-BD66-632A26F0BB8E

Q33986236-68179872-55D9-43BF-9A32-D152A224DB13

Q33986236-6CEEE261-7DFB-492E-93D7-71A512269D44

Q33986236-70BE0CCC-F721-4B2F-84C5-A186CE633859

Q33986236-79B85452-3173-4AB8-8B1A-AB04E99CD4DF

P2888

Q33986236-981371DA-CF24-4C1F-9AB0-583984D5457F

P304

Q33986236-B956EECA-B118-4284-8F24-1E17F8513E33

P31

Q33986236-CA9F03CF-9BA5-4AC3-940F-0E87EE682877

P356

Q33986236-08A4C0AB-B253-41AA-B7A0-148D17A4EDDB

P433

Q33986236-C5D7E25D-3C2D-444E-AA3A-C12F1A245753

P478

Q33986236-4FCDF844-C87D-49EE-A7EB-72972148F211

P577

Q33986236-ED9F8B06-8213-4778-8F0E-4247EAFA7409

P6179

Q33986236-0E9965DF-DB48-4E7C-A6FF-CF068026C424

P698

Q33986236-E9448DF7-E983-47CC-B236-BC1693313C82

P921

Q33986236-42502D91-5D14-427E-9EC1-9EB306822C87

Q33986236-D54B9D8C-683F-49B7-A2B6-F64C2AFCA515

Q33986236-F0A78F7C-4776-485A-B7AD-00DE7D5D6F66

P932

Q33986236-7420300F-3715-4344-BD89-227165EAD635

P356

P1433

P1476

Phase IB study of the FLT3 kin ...... s with acute myeloid leukemia.

@en

P2093

A Huntsman-Labed

http://www.w3.org/2001/XMLSchema#string

A del Corral

http://www.w3.org/2001/XMLSchema#string

C A Schiffer

http://www.w3.org/2001/XMLSchema#string

C Dutreix

http://www.w3.org/2001/XMLSchema#string

D J DeAngelo

http://www.w3.org/2001/XMLSchema#string

F Giles

http://www.w3.org/2001/XMLSchema#string

G Ehninger

http://www.w3.org/2001/XMLSchema#string

G Schiller

http://www.w3.org/2001/XMLSchema#string

H M Kantarjian

http://www.w3.org/2001/XMLSchema#string

J Cortes

http://www.w3.org/2001/XMLSchema#string

P2860

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

P2888

P304

2061-2068

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2012.115

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048055076

http://www.w3.org/2001/XMLSchema#string

P698

22627678

http://www.w3.org/2001/XMLSchema#string

P921

P932

4118284

http://www.w3.org/2001/XMLSchema#string